L K Martin1, X Li2, B Kleiber3, E C Ellison4, M Bloomston5, M Zalupski6, T S Bekaii-Saab7. 1. Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus. 2. Center for Biostatistics, The Ohio State University, Columbus. 3. Comprehensive Cancer Center, The Ohio State University, Columbus. 4. Department of Surgery, Division of General Surgery, The Ohio State University Medical Center, Columbus. 5. Department of Surgery, Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus. 6. Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA. 7. Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus. Electronic address: tanios.bekaii-saab@osumc.edu.
Abstract
BACKGROUND: We investigated the safety and efficacy of bevacizumab combined with gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreas cancer (APCA). DESIGN: Patients with untreated APCA received bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2) over 100 min, and 5-FU 2400 mg/m(2) over 48 h on days 1 and 15 of each 28-day cycle. The primary end point was the proportion of patients with progression-free survival (PFS) at 6 months from initiation of therapy. If PFS at 6 months was ≥41%, the regimen would be considered promising. RESULTS: Forty-two patients were enrolled in the study; of which, 39 were evaluable for primary end point. PFS at 6 months was 49% (95% CI 34% to 64%). Median PFS was 5.9 months (95% CI 3.5 to 8.1) and median overall survival (OS) was 7.4 months (95% CI 4.7 to 11.2). Partial response and stable disease occurred in 30% and 45% of patients, respectively. Treatment-related hypertension and normal baseline albumin correlated with an improved response rate, PFS and OS. Grade 3 to 4 toxicities included fatigue (14%), hypertension (5%), and venous thrombosis (5%). CONCLUSIONS: The study met its primary end point. Further investigation of anti-VEGF therapy in combination with fluoropyrimidine-based therapy is warranted in APCA. Treatment-related hypertension and normal baseline albumin may predict for the efficacy of bevacizumab and should be investigated in prospective studies.
BACKGROUND: We investigated the safety and efficacy of bevacizumab combined with gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreas cancer (APCA). DESIGN:Patients with untreated APCA received bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2) over 100 min, and 5-FU 2400 mg/m(2) over 48 h on days 1 and 15 of each 28-day cycle. The primary end point was the proportion of patients with progression-free survival (PFS) at 6 months from initiation of therapy. If PFS at 6 months was ≥41%, the regimen would be considered promising. RESULTS: Forty-two patients were enrolled in the study; of which, 39 were evaluable for primary end point. PFS at 6 months was 49% (95% CI 34% to 64%). Median PFS was 5.9 months (95% CI 3.5 to 8.1) and median overall survival (OS) was 7.4 months (95% CI 4.7 to 11.2). Partial response and stable disease occurred in 30% and 45% of patients, respectively. Treatment-related hypertension and normal baseline albumin correlated with an improved response rate, PFS and OS. Grade 3 to 4 toxicities included fatigue (14%), hypertension (5%), and venous thrombosis (5%). CONCLUSIONS: The study met its primary end point. Further investigation of anti-VEGF therapy in combination with fluoropyrimidine-based therapy is warranted in APCA. Treatment-related hypertension and normal baseline albumin may predict for the efficacy of bevacizumab and should be investigated in prospective studies.
Authors: Hedy Lee Kindler; Donna Niedzwiecki; Donna Hollis; Susan Sutherland; Deborah Schrag; Herbert Hurwitz; Federico Innocenti; Mary Frances Mulcahy; Eileen O'Reilly; Timothy F Wozniak; Joel Picus; Pankaj Bhargava; Robert J Mayer; Richard L Schilsky; Richard M Goldberg Journal: J Clin Oncol Date: 2010-07-06 Impact factor: 44.544
Authors: Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: M Scartozzi; E Galizia; S Chiorrini; R Giampieri; R Berardi; C Pierantoni; S Cascinu Journal: Ann Oncol Date: 2008-10-07 Impact factor: 32.976
Authors: Yuval Shaked; Erik Henke; Jeanine M L Roodhart; Patrizia Mancuso; Marlies H G Langenberg; Marco Colleoni; Laura G Daenen; Shan Man; Ping Xu; Urban Emmenegger; Terence Tang; Zhenping Zhu; Larry Witte; Robert M Strieter; Francesco Bertolini; Emile E Voest; Robert Benezra; Robert S Kerbel Journal: Cancer Cell Date: 2008-09-09 Impact factor: 31.743
Authors: Shubham Pant; Ludmila K Martin; Susan Geyer; Lai Wei; Katherine Van Loon; Nili Sommovilla; Mark Zalupski; Renuka Iyer; David Fogelman; Andrew H Ko; Tanios Bekaii-Saab Journal: Am J Clin Oncol Date: 2016-12 Impact factor: 2.339
Authors: Shubham Pant; Ludmila K Martin; Susan Geyer; Lai Wei; Katherine Van Loon; Nili Sommovilla; Nilli Sommovilla; Mark Zalupski; Renuka Iyer; David Fogelman; Andrew H Ko; Tanios Bekaii-Saab Journal: Cancer Date: 2014-03-13 Impact factor: 6.860
Authors: Katherine Van Loon; Anne M Espinoza; David R Fogelman; Robert A Wolff; Milind M Javle; Renuka V Iyer; Vincent J Picozzi; Ludmila Katherine Martin; Tanios Bekaii-Saab; Margaret A Tempero; Nathan R Foster; George P Kim; Andrew H Ko Journal: Pancreas Date: 2014-04 Impact factor: 3.327
Authors: Andrew X Zhu; Richard S Finn; Mary Mulcahy; Jayne Gurtler; Weijing Sun; Jonathan D Schwartz; Rita P Dalal; Adarsh Joshi; Rebecca R Hozak; Yihuan Xu; Marek Ancukiewicz; Rakesh K Jain; Francis W Nugent; Dan G Duda; Keith Stuart Journal: Clin Cancer Res Date: 2013-10-02 Impact factor: 12.531
Authors: Elizabeth J Davis; Kent A Griffith; Edward J Kim; Joshua M Ruch; Kevin J McDonnell; Mark M Zalupski Journal: Am J Clin Oncol Date: 2018-02 Impact factor: 2.339